Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment

Reuters

2025/05/16

Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment

Sihuan Pharmaceutical Holdings Group Ltd. has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535357053"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535357053\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535357053?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 11:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535357053","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-16 11:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工業大麻","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL747RlM:1","article_id":"2535357053","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535357053","pubTimestamp":1747367882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. has announced the approval of Bireociclib tablets  by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1600":"工业大麻","00460":"四环医药","BK1191":"制药","BK1515":"抗疫概念","BK1593":"医美概念股"},"translate_title":"四环医药玄月宁®片获批双适应症乳腺癌治疗取得突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9},"content_text":"Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n    \n\nSihuan Pharmaceutical Holdings Group Ltd. has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}